gp100 peptide-major histocompatibility complex (gp100 pMHC complex)

The gp100 peptide-major histocompatibility complex is a molecular complex formed when a peptide derived from the melanoma antigen gp100 (most commonly amino acids 209–217 or similar variants) is presented on the cell surface by major histocompatibility complex (MHC) molecules, particularly HLA-A*0201 (class I MHC) or HLA-DRB1*0401 (class II MHC)[2][5][7]. This complex is not a natural standalone protein but rather a composite structure that is the central molecular target for T-cell recognition in antigen-specific cancer immunotherapies and cancer vaccines. T-cell receptors (TCRs) on cytotoxic and helper T-cells recognize the gp100 peptide when bound to the appropriate MHC, leading to immune activation and targeted killing of melanoma cells that express this antigen. The composition, conformation, and dynamics of this complex—arising from both the peptide sequence and its anchoring within the MHC groove—directly influence its immunogenicity, therapeutic targeting, and risk of autoimmune toxicity[1][3][7]. The gp100 peptide-MHC complex is a validated therapeutic target, especially for TCR-based immunotherapies and immune-mobilizing antibodies such as tebentafusp, and forms the molecular basis of several experimental and approved cancer therapies targeting melanoma[7].

Other names

gp100/HLAgp100 peptide-MHCgp100209/HLA-A2 (for the commonly studied epitope)gp100 pMHC

T-cell engagement via TCR recognition of the gp100 peptide-MHC complex, leading to cytotoxic T-cell-mediated killing of tumor cells expressing this antigenic peptide[1][5][7]. Bispecific fusion proteins (e.g., tebentafusp) link T-cells to melanoma cells expressing gp100 pMHC, redirecting immune responses to tumor cells.